MedDataX Logo

The Chinese-made Praziquantel for Treatment of Schistosoma Haematobium

NCT ID: NCT03133832

Last Updated: 2017-04-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-10

Study Completion Date

2017-07-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Schistosomiasis remains an important parasitic disease in the tropics, special in Africa including Zanzibar. The WHO-recommended strategy to eliminate schistosomiasis involves large-scale treatment of affected populations through periodic, targeted treatment of school-children with praziquantel. Donated praziquantel is the key to achieving elimination. The increase in the number of treatments is attributable to many factors, including improved availability of donated praziquantel, essentially from Merck; new countries starting to implement large-scale schistosomiasis control programmes; geographical scale-up of treatment within countries; and improved reporting to WHO. The global target set by WHO in the Roadmap on neglected tropical diseases is to attain at least 75% coverage of preventive chemotherapy in pre-school and school-age children by 2020. Experience from China demonstrates that preventive chemotherapy (that is, large scale treatment without individual diagnosis) with high coverage can significantly impact indices of infection and reduce transmission. The praziquantel made in China has been used from 1990s, and have effectively activity against S. haematobium, special the good economic benefits.

The project will propose to conduct an open-label, randomized trial to evaluate the comparative efficacy of Chinese-made Praziquantel versus WHO Praziquantel in the treatment of 200 people infected with S. haematobium in Pemba island Zanzibar. To do this the investigators will screen about 4000 people by examination of urine for schistosome eggs. Eligible participants will be randomized to receive a single dose of Chinese-made and WHO Praziquantel. Four weeks after treatment, the participants will be assessed for cure and egg reduction. The study may provide an alternative drug treatment for S. haematobium.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants There about 4000 peoples (aged 7-60 years) were enrolled from three Shehias in Pemba island Zanzibar. Urine will be collected and tested on April 2017. Eligible people will be enrolled based on the criteria of inclusion and exclusion. A series of meetings will be held at Shehias and schools to explain the objectives, procedures, and potential risks of the study.

Randomization Participants were randomly assigned (1:1) to receive Chinese-made versus WHO-PQ praziquantel. The randomization sequence was computer generated by the study sponsor. The staff of NTD office will give the assigned study drug after confirming the treatment allocation from the randomisation sequence. The NTD staff and and study participants will be unmasked to treatment assignment, but the laboratory technicians will be masked to treatment assignment throughout the study.

Procedures Firstly, every participant provided a fresh urine sample, which was used to detect the presence of S. haematobium. The NTD staff will do a physical examination, and checked the eligibility of every participant.

Participants whose urines tested positive for S. haematobium eggs and who met all eligibility criteria were invited to participate in the study.

Chines-made and WHO-PQ praziquantel will be give the participants one dose of 40 mg/kg per day. All study drugs were given orally, and the NTD staff will also record the exact time of drug ingestion.

Participants will be observed for 2 h after taking the drug to ensure retention and check for any immediate adverse events. If vomiting occurred within 2 h of drug ingestion, a second full dose was given.

After one month after enrolment, the follow-up visit will be provided, and urine will be collected and tested for S. haematobium eggs. As a quality control measure for inter-observer variability, a third technician reread a random selection of 10% of slides.

An adverse event is defined as a sign, symptom, intercurrent illness, or abnormal laboratory finding that just occurred during follow-up.

At the end of the study, all participants who have still excreting S. haematobium eggs (ie, not cured) will be treated with praziquantel again.

Statistical analysis There serial report forms will be used to data collection from participants, and Epi Info will be used to data enter.

The cure rate, the mean egg count and economic benefits will be analysed between the different group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schistosomiasis Haematobia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Schistosomiasis haematobium Praziquantel A randomized controlled trial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

The cure rate between the two treatment

Compare the cure rate between the Chinese-made praziquantel and companion tablet at one dose of 40 mg/kg

Group Type EXPERIMENTAL

Companion Tablet

Intervention Type DRUG

Chinese-made drug for schistosomiasis treatment

The amount of eggs produced

Compare the amount of eggs produced between the Chinese-made praziquantel and companion tablet at one dose of 40 mg/kg

Group Type EXPERIMENTAL

Companion Tablet

Intervention Type DRUG

Chinese-made drug for schistosomiasis treatment

The economic benefit

Compare the economic benefit between the Chinese-made praziquantel and companion tablet at one dose of 40 mg/kg

Group Type EXPERIMENTAL

Companion Tablet

Intervention Type DRUG

Chinese-made drug for schistosomiasis treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Companion Tablet

Chinese-made drug for schistosomiasis treatment

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Chinese-made praziquantel

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged between 7 and 60 years old
* Study participants appear healthy at enrollment
* Suffering from S. haematobium infection, excreting eggs in urine
* Residing in Pemba island, Zanzibar
* Able to receive oral treatment
* Assent to participate in study

Exclusion Criteria

* Pregnant or lactating at the time of the study
* Presence of severe illness or malnutrition
* Hypersensitivity to PZQ.
Minimum Eligible Age

7 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

World Health Organization

OTHER

Sponsor Role collaborator

Jiangsu Institute of Parasitic Diseases

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

YANG KUN

Deputy director

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kun Yang, PHD

Role: PRINCIPAL_INVESTIGATOR

Jiangsu Institute of Parasitic Diseases

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

NTD office, Pemba,Ministry of Health, Zanzibar

Pemba, Zanzibar, Tanzania

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Tanzania

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kun Yang, PHD

Role: CONTACT

Phone: +8613656190585

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Saleh Juma, Master

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Wang XY, He J, Juma S, Kabole F, Guo JG, Dai JR, Li W, Yang K. Efficacy of China-made praziquantel for treatment of Schistosomiasis haematobium in Africa: A randomized controlled trial. PLoS Negl Trop Dis. 2019 Apr 10;13(4):e0007238. doi: 10.1371/journal.pntd.0007238. eCollection 2019 Apr.

Reference Type DERIVED
PMID: 30969960 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

JIPD2017001

Identifier Type: -

Identifier Source: org_study_id